The global Xerostomia Therapeutics Market was valued at USD 2.13 billion in 2024, projected to reach USD 2.87 billion by 2032 with a CAGR of 3.82%. Factors contributing to dry mouth include aging, medications, and chronic diseases such as diabetes. The U.S. market is expected to grow from USD 0.67 billion in 2024 to USD 0.89 billion by 2032.
Government initiatives and healthcare guidelines are driving demand for xerostomia treatment, emphasizing early diagnosis and management. New formulations aiming to improve tolerability and efficacy are being promoted by manufacturers. Health providers underscore the oral health risks associated with untreated xerostomia, such as tooth decay and infections.
The OTC segment holds a 58% market share in xerostomia therapy, expected to maintain strong growth during the forecast period. Salivary stimulants, comprising 36% of the market share in 2024, led the market due to clinical effectiveness. Dentifrices are expected to have the fastest CAGR, driven by rising awareness of oral health and dental problems linked with xerostomia.
North America held 40% of the xerostomia therapeutics market share in 2024, with Asia Pacific expected to exhibit the fastest CAGR of 4.33% throughout the forecast period. The Asia-Pacific region’s growth is fueled by rising healthcare costs, an aging population, and an increased frequency of chronic diseases causing xerostomia.
Recent news includes positive results from GSK’s EAGLE-1 Phase III study for a novel oral treatment for gonorrhea. MeiraGTx gained FDA’s RMAT designation for treating radiation-induced xerostomia. The report provides exclusive sections such as pharmaceutical volume metrics, healthcare spending analysis, regulatory landscape, therapeutic pipeline, and market access readiness index.
S&S Insider is a leading market research and consulting agency focusing on providing clients with the knowledge they need to navigate changing circumstances. Their goal is to offer current and accurate market data, consumer insights, and opinions to enable confident decision-making. 1. The stock market saw a significant drop today, with the S&P 500 falling 3% and the Dow Jones Industrial Average dropping 500 points. Investors are concerned about rising inflation rates and the possibility of a recession.
2. The latest unemployment numbers are in, showing a slight increase in jobless claims. The Labor Department reported that 230,000 people filed for unemployment benefits last week, up from 210,000 the previous week.
3. A new study has found that air pollution is linked to an increased risk of heart disease. Researchers found that exposure to high levels of air pollution can lead to inflammation in the arteries, increasing the risk of heart attacks and strokes.
4. The FDA has approved a new drug for the treatment of Alzheimer’s disease. Aduhelm, developed by Biogen, is the first drug to receive approval for Alzheimer’s in nearly 20 years. However, some experts have raised concerns about the drug’s effectiveness and high cost.
Read more at GlobeNewswire: Xerostomia Drugs Market to Reach USD 2.87 Billion by 2032